research use only

Verapamil Calcium Channel antagonist

Name: Verapamil
Brand: Selleck Chemicals
SKU: E4980
Availability: InStock
Rating: 5 (5 reviews)

Cat.No.E4980

Verapamil(Iproveratril,Dilacoran), is a phenylalkylamine derivative which is an antagonist of calcium influx and also an inhibitor P-gp and CYP3A4. It exhibits potency in treatment for angina, cardiac arrhythmias, cardiomyopathies and hypertension.

Chemical Structure

Molecular Weight: 454.60

Jump to

Quality Control

Batch: E498001 DMSO]91 mg/mL]false]Ethanol]91 mg/mL]false]Water]22 mg/mL]false Purity: 99.54%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.54

Related Targets	CFTR CRM1 CD markers AChR Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR
Other Calcium Channel Inhibitors	Bay K 8644 BAPTA-AM Tetrandrine Flunarizine 2HCl Nilvadipine Cilnidipine YM-58483 (BTP2) Ionomycin Imperatorin Manidipine 2HCl

Solubility

In vitro
Batch:

DMSO : 91 mg/mL (200.17 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 91 mg/mL

Water : 22 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	454.60	Formula	C₂₇H₃₈N₂O₄	Storage (From the date of receipt)	2 years -20°C liquid
CAS No.	52-53-9	Download SDF		Storage (From the date of receipt)	2 years -20°C liquid

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	Calcium channel P-gp CYP3A4
References	[1] https://pubmed.ncbi.nlm.nih.gov/2670511/ [2] https://pubmed.ncbi.nlm.nih.gov/29523051/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-17)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07655440	NOT_YET_RECRUITING	Migraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine	Stanford University	2026-07	PHASE4
NCT07061574	RECRUITING	Type 1 Diabetes; New Onset	City of Hope Medical Center	2026-03-10	PHASE1; PHASE2
NCT07199946	RECRUITING	Type 1 Diabetes	Johnny Ludvigsson	2025-08-06	PHASE1; PHASE2
NCT07445789	NOT_YET_RECRUITING	Atrial Fibrillation (AF)	Martini Hospital Groningen	2026-06	PHASE4
NCT06455319	RECRUITING	Type 1 Diabetes	University of Florida	2025-11-12	PHASE2
NCT07688070	NOT_YET_RECRUITING	Cystic Fibrosis Related Diabetes; Cystic Fibrosis (CF); Abnormal Glucose Tolerance	Rhode Island Hospital	2026-08-01	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):